# A Study to Assess the Effects of Brolucizumab in Adult Patients With Neovascular Age Related Macular Degeneration

> **NCT04239027** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 210 (actual)

## Conditions studied

- Neovascular Age Related Macular Degeneration

## Interventions

- **DRUG:** RTH258/Brolucizumab

## Key facts

- **NCT ID:** NCT04239027
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-26
- **Primary completion:** 2022-05-23
- **Final completion:** 2023-02-02
- **Target enrollment:** 210 (ACTUAL)
- **Last updated:** 2024-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04239027

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04239027, "A Study to Assess the Effects of Brolucizumab in Adult Patients With Neovascular Age Related Macular Degeneration". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04239027. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*